FDA approves first PSMA-targeted PET imaging drug for in prostate cancer

Early-onset cancer is on the rise. Here is how OSUCCC–James is adapting to the needs of younger patients

The incidence of multiple cancer types in people under the age of 50 has been rising, with early-onset cancers now contributing to nearly 15,000 excess cases of cancer in the U.S. annually.

March 27, 2026

By W. Kimryn Rathmell

Trials & Tribulations

In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt

March is National Colorectal Cancer Awareness Month. It is a reminder of a heartbreaking trend that oncologists like me are witnessing in our clinics: Last year, for the first time, colorectal cancer became the leading cause of cancer-related death in Americans under the age of 50, according to data published earlier this year in JAMA.

March 27, 2026

By Richard M. Goldberg

Clinical

Colorectal cancer is now the leading cause of cancer death in patients under 50
Why aren’t 45-year-olds getting their recommended CRC screenings?

Three decades ago, colorectal cancer was the fifth leading cause of cancer death in patients under 50 years old. For a physician treating the average 45-year-old, colorectal cancer was not a diagnosis that immediately came to mind.

March 27, 2026

By Sara Willa Ernst

Obituary

Michael Bishop, Nobel-winning cancer researcher, dies at 90

UC San Francisco Chancellor emeritus J. Michael Bishop, a pioneering microbiologist who shared the 1989 Nobel Prize in Physiology or Medicine for discovering that every cell in the body harbors genes that can cause cancer, died March 20. He was 90.

March 27, 2026

By UCSF Communications Staff

Podcast

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

Last week’s issue of The Cancer Letter was dominated by one event: the meeting of the National Cancer Advisory Board, the group of experts which advises and assists the NCI director on the activities of the National Cancer Program.

March 25, 2026

NCI

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”

A public-private effort, spearheaded by NCI Director Anthony Letai, and led by the Foundation for the National Institutes of Health, is working to speed up the development of therapeutic cancer vaccines.

March 20, 2026

Vol.52 No.11

By Claire Marie Porter

FDA approves first PSMA-targeted PET imaging drug for in prostate cancer

YOU MAY BE INTERESTED IN

Early-onset cancer is on the rise. Here is how OSUCCC–James is adapting to the needs of younger patients

In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt

Colorectal cancer is now the leading cause of cancer death in patients under 50
Why aren’t 45-year-olds getting their recommended CRC screenings?

Michael Bishop, Nobel-winning cancer researcher, dies at 90

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”

Renew today!

Subscriber content

Never miss an issue!

Login

FDA approves first PSMA-targeted PET imaging drug for in prostate cancer

YOU MAY BE INTERESTED IN

Early-onset cancer is on the rise. Here is how OSUCCC–James is adapting to the needs of younger patients

In the era of immunotherapy, response rate alone fails to predict true patient benefitRegulators must adapt

Colorectal cancer is now the leading cause of cancer death in patients under 50Why aren’t 45-year-olds getting their recommended CRC screenings?

Michael Bishop, Nobel-winning cancer researcher, dies at 90

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccinesNCI Director Letai: “How aggressive can we be?”

Never miss an issue!

Login

In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt

Colorectal cancer is now the leading cause of cancer death in patients under 50
Why aren’t 45-year-olds getting their recommended CRC screenings?

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”